ITT (ITT)

Search documents
Behrman Capital to Sell Portfolio Company kSARIA to ITT for $475 Million
Prnewswire· 2024-08-01 13:34
NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Behrman Capital, a private equity investment firm based in New York, today announced that it has entered into a definitive agreement to sell its portfolio company kSARIA Holdings ("kSARIA" or "the company"), a leading producer and supplier of mission-critical connectivity solutions for the aerospace and defense end markets, to ITT Inc. ("ITT", NYSE: ITT) in a transaction valued at approximately $475 million. Founded in 2000, kSARIA brings extensive process technology a ...
ITT (ITT) Tops Q2 Earnings Estimates
ZACKS· 2024-08-01 12:50
ITT (ITT) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 2.05%. A quarter ago, it was expected that this supplier of parts and services to a wide variety of industries would post earnings of $1.36 per share when it actually produced earnings of $1.42, delivering a surprise of 4.41%. ...
ITT (ITT) - 2024 Q2 - Quarterly Results
2024-08-01 11:19
Exhibit 99.1 ITT REPORTS 2024 SECOND QUARTER EARNINGS PER SHARE (EPS) OF $1.45, ADJUSTED EPS OF $1.49; ANNOUNCES PORTFOLIO RESHAPING WITH ACQUISITION OF INTERCONNECT SOLUTIONS PROVIDER kSARIA AND DIVESTITURE OF AUTOMOTIVE COMPONENTS SUPPLIER WOLVERINE ▪ 9% revenue growth (6% organic) driven by higher sales volumes across all segments and the acquisition of Svanehøj ▪ 60 basis points operating margin expansion to 17.6%; 100 basis points adjusted operating margin expansion to 18.0% ▪ 11% EPS growth (12% adjus ...
Unveiling ITT (ITT) Q2 Outlook: Wall Street Estimates for Key Metrics
ZACKS· 2024-07-31 14:21
Based on the collective assessment of analysts, 'Operating income (Non gaap)- Industrial Process' should arrive at $71.18 million. Compared to the present estimate, the company reported $67.10 million in the same quarter last year. The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. While investors usually ...
Here's Why You Should Add ITT Stock to Your Portfolio Now
ZACKS· 2024-07-11 14:10
Carlisle Companies Incorporated (CSL) presently carries a Zacks Rank #2 (Buy). It has a trailing four-quarter average earnings surprise of 17%. The consensus estimate for CSL's 2024 earnings has increased 2.2% in the past 60 days. Shares of Carlisle have risen 57.9% in the past year. Griffon Corporation (GFF) presently carries a Zacks Rank of 2. It delivered a trailing four-quarter average earnings surprise of 33.5%. In the past 60 days, the Zacks Consensus Estimate for GFF's 2024 earnings has increased 4.2 ...
Reasons Why ITT Stock Deserves to Be in Your Portfolio Now
ZACKS· 2024-06-11 15:26
ITT Inc. (ITT) stands to benefit from strength across its businesses, acquisitions and focus on operational excellence. The company remains focused on investing in growth opportunities and strengthening its long-term market position. It has a market capitalization of $10.5 billion. Over the past six months, it has gained 12.1%, compared with the industry's growth of 0.8%. ITT currently carries a Zacks Rank #2 (Buy). Image Source: Zacks Investment Research Let's delve into the factors that have been aiding t ...
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
GlobeNewswire News Room· 2024-06-06 09:00
Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for accelerated approval in MASH Statistical significance also shown in improvement of liver fibrosis ≥2-stage without worsening of MASH in the mITT population, including in patients with baseline stage 3 fibrosis Tripalmitin, a biomarker of denifanstat activity, showed an early and sustained reduction in de nov ...
ITT (ITT) - 2024 Q1 - Earnings Call Transcript
2024-05-02 18:49
Emmanuel Caprais Good morning, Michael. Great. Really appreciate everyone. Thank you. had such a long backlog. So we have good line-of-sight to bring Axtone to the mid to-high teens this year. But I would say, rail margins, especially in KONI are trending really well. Sure. Well, about it, Joe. I think that despite the big headwinds of mix, the margin improved more than 140 basis-points on an organic basis on a like-for-like. And the reason is really the result of the selectivity that we had in other acquis ...
Compared to Estimates, ITT (ITT) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research· 2024-05-02 15:07
For the quarter ended March 2024, ITT (ITT) reported revenue of $910.6 million, up 14.1% over the same period last year. EPS came in at $1.42, compared to $1.17 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $873.58 million, representing a surprise of +4.24%. The company delivered an EPS surprise of +4.41%, with the consensus EPS estimate being $1.36.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they comp ...
ITT (ITT) - 2024 Q1 - Earnings Call Presentation
2024-05-02 15:02
Q1 2023 Q4 2023 Q1 2024 • Strength in IP service and valves; short cycle +9% sequentially Q1 SUMMARY RESULTS $798M $911M Q1 2023 Q1 2024 +23% + Shop floor productivity + >200 bps pump projects margin improvement $1.17 $1.42 1 Q1 2023 Q1 2024 0.5 0.6 0.7 0.8 0.9 1.1 1.2 1.3 1.4 + Profitable growth FREE CASH FLOW - A/R collections timing, higher incentive compensation All results unaudited. Comparisons to Q1 2023 unless otherwise noted. For non-GAAP reconciliations, refer to appendix. M&A, net Strategic Initi ...